These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 23116391)
1. D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Sacchi S; Rosini E; Pollegioni L; Molla G Curr Pharm Des; 2013; 19(14):2499-511. PubMed ID: 23116391 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Ferraris DV; Tsukamoto T Curr Pharm Des; 2011; 17(2):103-11. PubMed ID: 21361869 [TBL] [Abstract][Full Text] [Related]
3. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model. Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796 [TBL] [Abstract][Full Text] [Related]
4. Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase. Frattini LF; Piubelli L; Sacchi S; Molla G; Pollegioni L FEBS J; 2011 Nov; 278(22):4362-73. PubMed ID: 21981077 [TBL] [Abstract][Full Text] [Related]
5. Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies. Szilágyi B; Ferenczy GG; Keserű GM Expert Opin Drug Discov; 2018 Oct; 13(10):973-982. PubMed ID: 30220232 [TBL] [Abstract][Full Text] [Related]
6. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Strick CA; Li C; Scott L; Harvey B; Hajós M; Steyn SJ; Piotrowski MA; James LC; Downs JT; Rago B; Becker SL; El-Kattan A; Xu Y; Ganong AH; Tingley FD; Ramirez AD; Seymour PA; Guanowsky V; Majchrzak MJ; Fox CB; Schmidt CJ; Duplantier AJ Neuropharmacology; 2011; 61(5-6):1001-15. PubMed ID: 21763704 [TBL] [Abstract][Full Text] [Related]
7. Characterization of human D-amino acid oxidase. Molla G; Sacchi S; Bernasconi M; Pilone MS; Fukui K; Polegioni L FEBS Lett; 2006 Apr; 580(9):2358-64. PubMed ID: 16616139 [TBL] [Abstract][Full Text] [Related]
9. Metabolism of the neuromodulator D-serine. Pollegioni L; Sacchi S Cell Mol Life Sci; 2010 Jul; 67(14):2387-404. PubMed ID: 20195697 [TBL] [Abstract][Full Text] [Related]
10. Oral administration of D-alanine in monkeys robustly increases plasma and cerebrospinal fluid levels but experimental D-amino acid oxidase inhibitors had minimal effect. Rojas C; Alt J; Ator NA; Wilmoth H; Rais R; Hin N; DeVivo M; Popiolek M; Tsukamoto T; Slusher BS J Psychopharmacol; 2016 Sep; 30(9):887-95. PubMed ID: 27287825 [TBL] [Abstract][Full Text] [Related]
11. Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research. Kuo CY; Lin CH; Lane HY CNS Drugs; 2022 Nov; 36(11):1143-1153. PubMed ID: 36194364 [TBL] [Abstract][Full Text] [Related]
12. Structure-function relationships in human D-amino acid oxidase. Sacchi S; Caldinelli L; Cappelletti P; Pollegioni L; Molla G Amino Acids; 2012 Nov; 43(5):1833-50. PubMed ID: 22865246 [TBL] [Abstract][Full Text] [Related]
13. Factors regulating serine racemase and d-amino acid oxidase expression in the mouse striatum. Takagi S; Balu DT; Coyle JT Brain Res; 2021 Jan; 1751():147202. PubMed ID: 33171153 [TBL] [Abstract][Full Text] [Related]
14. Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. Caldinelli L; Molla G; Bracci L; Lelli B; Pileri S; Cappelletti P; Sacchi S; Pollegioni L Protein Sci; 2010 Aug; 19(8):1500-12. PubMed ID: 20521334 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. Rais R; Thomas AG; Wozniak K; Wu Y; Jaaro-Peled H; Sawa A; Strick CA; Engle SJ; Brandon NJ; Rojas C; Slusher BS; Tsukamoto T Drug Metab Dispos; 2012 Nov; 40(11):2067-73. PubMed ID: 22837388 [TBL] [Abstract][Full Text] [Related]
16. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. Smith SM; Uslaner JM; Yao L; Mullins CM; Surles NO; Huszar SL; McNaughton CH; Pascarella DM; Kandebo M; Hinchliffe RM; Sparey T; Brandon NJ; Jones B; Venkatraman S; Young MB; Sachs N; Jacobson MA; Hutson PH J Pharmacol Exp Ther; 2009 Mar; 328(3):921-30. PubMed ID: 19088300 [TBL] [Abstract][Full Text] [Related]
17. Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. Szilágyi B; Kovács P; Ferenczy GG; Rácz A; Németh K; Visy J; Szabó P; Ilas J; Balogh GT; Monostory K; Vincze I; Tábi T; Szökő É; Keserű GM Bioorg Med Chem; 2018 May; 26(8):1579-1587. PubMed ID: 29472125 [TBL] [Abstract][Full Text] [Related]
18. D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog. Rojas C; Alt J; Ator NA; Thomas AG; Wu Y; Hin N; Wozniak K; Ferraris D; Rais R; Tsukamoto T; Slusher BS Neuropsychopharmacology; 2016 May; 41(6):1610-9. PubMed ID: 26471255 [TBL] [Abstract][Full Text] [Related]